telmisartan has been researched along with Angiogenesis, Pathologic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiyo, T; Fujihara, S; Himoto, T; Iwama, H; Kobara, H; Kobayashi, K; Masaki, T; Mori, H; Morishita, A; Nakahara, M; Okano, K; Oura, K; Samukawa, E; Suzuki, Y; Tadokoro, T; Yamana, Y | 1 |
| Gu, Y; Körbel, C; Laschke, MW; Menger, MD; Nenicu, A | 1 |
| Aso, K; Haneda, M; Kanamori, H; Makino, Y; Nakade, Y; Nakao, H; Ohashi, T; Okada, M; Sato, K; Tamaki, Y; Yamauchi, T; Yokohama, S; Yoneda, M | 1 |
3 other study(ies) available for telmisartan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Benzimidazoles; Benzoates; Bile Duct Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; G1 Phase Cell Cycle Checkpoints; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neovascularization, Pathologic; Random Allocation; Resting Phase, Cell Cycle; Telmisartan; Xenograft Model Antitumor Assays | 2017 |
Combined blockade of angiotensin II type 1 receptor and activation of peroxisome proliferator-activated receptor-γ by telmisartan effectively inhibits vascularization and growth of murine endometriosis-like lesions.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; Down-Regulation; Endometriosis; Female; Gene Expression Profiling; Mice; Neovascularization, Pathologic; Peritoneal Diseases; Pioglitazone; PPAR gamma; Telmisartan; Thiazolidinediones; Up-Regulation | 2014 |
Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis.
Topics: Amino Acids; Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Benzimidazoles; Benzoates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Choline Deficiency; Diet; Drug Evaluation, Preclinical; Fatty Liver; Gene Expression Regulation; Hypoxia-Inducible Factor 1, alpha Subunit; Liver; Liver Cirrhosis; Liver Neoplasms, Experimental; Male; Neovascularization, Pathologic; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Telmisartan; Vascular Endothelial Growth Factor A | 2013 |